The association of a specific autoantibody response with distinct disease phenotypes is observed in both autoimmune diseases and cancer. Although the underlying mechanisms remain unclear, it is likely that unique properties of disease-specific autoantigens expressed in the relevant target cells play a role. It has recently been observed that the majority of autoantigens targeted across the spectrum of systemic autoimmune diseases (but not nonautoantigens) are selectively cleaved by the cytotoxic lymphocyte granule protease granzyme B (GB), generating unique fragments not observed during other forms of cell death. Although susceptibility of a molecule to cleavage by GB strongly predicts autoantigen status, the significance of this association is unclear. We used hepatocellular carcinoma and the hepatocellular carcinoma autoantigen, nucleophosmin͞B23, as a model system to define the unique features of disease-specific autoantigens in the relevant disease microenvironment. These studies revealed a striking, selective susceptibility of B23 to cleavage by GB in extracts of neoplastic liver. The increased sensitivity of tumor B23 to proteolysis by GB was accompanied by slightly increased mobility on SDS͞PAGE, altered subcellular localization, enrichment of an SDS-stable oligomeric form of B23, and recognition by a conformation-specific antibody detecting a B23 epitope ending at the GB cleavage site. In vitro studies demonstrated that this unique B23 conformation and resultant increased susceptibility to cleavage by GB arise when B23 translation is initiated at methionine-7. We propose that unique features of autoantigens in the disease-relevant microenvironment may regulate susceptibility to cleavage by GB and their selection by the specific autoimmune response.
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granzyme B ͉ hepatocellular carcinoma ͉ proteolysis ͉ nucleolus ͉ oligomer T here is a striking association between autoantigens targeted in various autoimmune diseases and the biological phenotype of the disease (1, 2) . Although the targeted molecules share little in common in control cells, most autoantigens are unified by their susceptibility to cleavage by granzyme B (GB) during cytotoxic lymphocyte granule-induced cell death, generating unique fragments not observed during other forms of cell death (3) (4) (5) (6) (7) (8) (9) . Interestingly, several studies demonstrate that immunization with fragments of self-proteins that are not generated during natural antigen-presenting pathways can elicit an autoimmune response (10, 11) . We have thus suggested that GB-mediated cleavage of autoantigens during cytotoxic lymphocyte granuleinduced death of target cells might produce unique autoantigen structure not previously encountered by the immune system, and thereby initiate a primary T cell response against the cleaved host protein (4, 5) .
The shared susceptibility of ubiquitously expressed autoantigens to cleavage by GB does not explain the striking association of specific autoantibodies with distinct disease phenotypes. We hypothesize that autoantigens exhibit immunologically distinct features in the disease-relevant microenvironment where initial immunization with self-proteins occurs. Because systemic autoimmune diseases involve multiple organs and cell types, and the site and cause of disease initiation has not yet been clearly defined for most diseases, studies to define the status of specific autoantigens in the immunizing tissue in systemic autoimmune diseases will be challenging. Because several autoantigens recognized by autoantibodies from patients with systemic autoimmune diseases [e.g., NOR-90 (12), fibrillarin (13) , and B23 (14, 15) ] can also be targeted in patients with hepatocellular carcinoma (HCC), we have defined the microenvironment-specific properties of HCC autoantigens in liver tumor.
HCC is a malignancy that is accompanied by an autoantibody response to nuclear proteins in Ϸ30% of patients (16) . Interestingly, Imai et al. (17) showed an increase in antinuclear antibody titer and change in specificity to recognition of nucleolar antigens preceding the diagnosis of HCC in patients with chronic liver disease and proposed that the patient autoantibodies may recognize antigens involved in the process of cellular transformation. Several targets of the antinucleolar autoantibody response in HCC were identified, including B23, fibrillarin, and NOR-90 (16) . Although the roles of these proteins in transformation are unclear, their levels are increased in cancer cells (18, 19) . Interestingly, B23 autoantibodies are also found in patients with other tumors (e.g., breast cancer) (20) , indicating that this immune response may indeed be linked to novel features of the transformed cell.
We demonstrate here that a conformationally distinct form of B23 is found in HCC, which is markedly more sensitive to cleavage by GB than the B23 isoform in normal or cirrhotic liver. The unique B23 conformation in liver tumor likely results from an N-terminal truncation of B23 present in tumor hepatocytes that forms SDS-stable, GB-sensitive oligomers. The conformationally distinct form of B23 is recognized by a novel antibody raised against the GB cleavage site loop. We propose that the strong association of a unique autoantibody response with a specific biologic phenotype reflects microenvironment-specific changes in the structure and cleavability of autoantigens during the initiating and propagating events that incite the autoimmune response in vivo.
Materials and Methods
Antibodies. A polyclonal rabbit antibody to B23 (R3434) was raised by immunizing rabbits with recombinant histidine-tagged B23, prepared as described (15) . R3434 antiserum was affinitypurified against recombinant B23 (21) . A conformation-specific anti-B23 antibody (R3956) was generated in rabbits by immunization with an 8-aa peptide of B23 (KLH-CKKVKLAAD, comprising the LAAD 161 GB cleavage site). This antibody immunoblots only the N-terminal 22-kDa GB cleavage fragment and does not detect intact B23. Detection of the 22-kDa fragment was abolished by competition of the antibody with the immunizing peptide (data not shown). The R3956 antiserum was affinity-purified against the immunizing peptide, using a SulfoLink Coupling Gel (Pierce), according to the manufacturer's directions. The MF393 rabbit anticaspase 3 antibody was used as described (22) .
Liver Tissue. Frozen samples of HCC and non-neoplastic liver obtained from surgical resection specimens were snap-frozen in liquid nitrogen and stored at Ϫ80°C for subsequent analysis. Immediately adjacent tissue was embedded in paraffin, and sections were stained by hematoxylin and eosin to confirm the tissue diagnosis. Frozen liver tumor was derived from the tumors of four patients with HCC, including three with typical HCC and one with fibrolamellar HCC. The corresponding nontumor tissue in three patients with typical HCC showed cirrhosis secondary to chronic hepatitis C (n ϭ 2) and chronic hepatitis B (n ϭ 1) viral infections with mild ongoing portal and lobular inflammation. The nontumorous liver from the one patient with fibrolamellar carcinoma appeared normal histologically. Formalin-fixed, paraffin-embedded human liver tissue from six patients with HCC (four with typical HCC and two with fibrolamellar HCC) was serially sectioned at 5 m. Each liver section used for immunohistochemistry contained neoplastic and non-neoplastic tissue. The non-neoplastic tissues from the four patients with typical moderately differentiated HCC showed cirrhosis secondary to chronic hepatitis C (n ϭ 3) and cryptogenic cirrhosis (n ϭ 1). (3) . GB cleavage reactions were carried out in Nonidet P-40 lysis buffer (1% Nonidet P-40͞20 mM Tris, pH 7.4͞150 mM NaCl͞1 mM EDTA) and incubated for 60 min at 37°C. Reactions were terminated by boiling in SDS gel sample buffer. Proteins were resolved by SDS͞PAGE and visualized by fluorography. GB cleavage efficiency (k cat ͞K M ) was determined by quantitating the percentage of substrate cleaved by densitometry and fitting the values to the first-order rate equation: percentage of substrate cleavage ϭ 100 ϫ (1 Ϫ e Ϫkcat⅐[E]/KM⅐time ).
Mutation of P1 Aspartic Acid Residues to Alanine in Putative GB
Cleavage Sites. A cDNA clone encoding B23 was used as a template to generate selected Asp 3 Ala substitutions in the putative GB substrate P 1 position. Mutagenesis was performed by using the QuikChange site-directed mutagenesis kit (Stratagene) and confirmed by sequencing.
Immunoblotting of B23 and NOR-90 in Tumor and Nontumor Liver
Extracts. Liver extracts were prepared by homogenization of frozen liver samples in Nonidet P-40 lysis buffer containing protease inhibitors at 4°C. Equal amounts of protein were boiled in sample buffer containing 2% SDS and 2-mercaptoethanol, electrophoresed on 12% SDS͞PAGE gels, and transferred to nitrocellulose. To detect oligomeric B23, unboiled liver samples were electrophoresed on 10% SDS͞PAGE minigels in sample buffer containing 0.1% SDS and 5 mM DTT. Immunoblots were performed by using R3434 to visualize B23, patient serum to detect NOR-90, and a mAb for vinculin (Sigma).
Cleavage of B23 in GB-Treated Liver Extracts. Normal, cirrhotic, or tumor liver extracts containing 2 mM iodoacetamide were incubated with increasing concentrations of purified GB at 37°C for 60 min. Intact B23 and the N-terminal GB cleavage fragment were immunoblotted with R3434 and R3956, respectively. Caspase 3 processing was analyzed by immunoblotting with MF393. For comparison of the GB cleavage efficiency of B23 in the nontumor (normal and cirrhotic; n ϭ 3) versus tumor (n ϭ 4) extracts, the catalytic constants were calculated for B23 cleavage in each extract at three different GB concentrations, and results were analyzed by using a two-tailed t test.
Immunohistochemistry on Paraffin Liver Sections. Paraffin liver sections were deparaffinized, microwaved, blocked, and incubated overnight at 4°C with 10 g͞ml affinity-purified R3434 or R3956. A horseradish peroxidase-conjugated anti-rabbit antibody was used in combination with a Liquid DAB SubstrateChromogen System (DAKO) for visualization. Sections were counterstained with hematoxylin, mounted, and photographed with a ϫ25 lens on a Zeiss Axiophot microscope. The staining specificity was confirmed by competition after incubating antibodies with a 1,000-fold excess of either recombinant B23 (for R3434) or immunizing peptide (for R3956) for 2 h at 4°C before use in immunohistochemistry.
Generation of N-Terminal Truncations in B23.
B23 cDNA was used as a template for PCR amplification with Pfu polymerase (Stratagene) to generate truncated B23 lacking the first 18 nt of the coding sequence such that translation is initiated at methionine-7 (M7-B23). The truncated and full-length forms of B23 were generated by IVTT and analyzed on 12% SDS͞PAGE minigels. Samples were either boiled in 2% SDS gel buffer or mixed with gel buffer containing 0.1% SDS and electrophoresed without boiling to preserve the SDS-stable B23 oligomer.
Results

B23 Is Efficiently
Cleaved by GB at VEED 122 and LAAD 161 . To examine whether B23 is a substrate for GB, a cDNA encoding B23 was used for IVTT. [ 35 S]Methionine B23 was incubated in the presence or absence of purified GB and cleaved by the protease (Fig. 1) . In contrast to several autoantigens targeted in systemic autoimmune disease (e.g., PARP and Mi-2), B23 was not cleaved by a panel of different caspases (see Fig. 5 , which is published as supporting information on the PNAS web site, www.pnas.org). Using a positional scanning combinatorial tetrapeptide library, the substrate specificity of GB has been determined (23) . This specificity is unique among the family of serine proteases and is similar to that of the caspase family of cysteine proteases in its near-absolute requirement for aspartic acid in the substrate P 1 position. Using the known specificity of GB and the size of the B23 fragments generated, potential GB cleavage sites in B23 were identified. These putative P 1 aspartic acid residues were mutated to alanine, and the effect of these mutations on the cleavage efficiency was determined. Mutation of D 122 3A abolished generation of the major 28-and 15-kDa fragments, and the D 161 3A mutation abolished generation of the 20-and 22-kDa fragments (Fig. 1) . A double mutant (D 122,161 A) abolished cleavage entirely (Fig. 1). B23 Cleavage in Liver Tumors. We initially examined B23 levels in equal protein amounts of detergent extracts derived from neoplastic liver, surrounding non-neoplastic cirrhotic liver, and normal liver. Representative histology of the liver samples used for analysis is shown in Fig. 2A . B23 protein expression was increased Ϸ2.5-fold in tumor liver compared with the corresponding nontumorous background liver (Fig. 2B) . Interestingly, levels of the HCC autoantigen NOR-90 were dramatically augmented, with expression observed exclusively in the tumor lysate (Fig. 2B) . NOR-90 and B23 expression were similarly increased in other liver tumors compared with the corresponding nontumorous background livers (data not shown). As an additional control for protein loading, vinculin levels were determined and found to be comparable in the different lysates (Fig. 2B) .
In addition to the different levels of B23 expressed in tumor compared with nontumor liver, B23 from tumor liver consistently migrated slightly faster on SDS͞PAGE. Despite a concerted effort to define a posttranslational modification responsible for this shift, our experiments demonstrated it likely reflects a slightly smaller version of B23 beginning at a methionine residue downstream from the initiator methionine (see below).
To determine whether the differences in B23 in tumor liver compared with nontumor liver could affect its susceptibility to cleavage by GB, equal protein amounts of liver tumor and nontumor extracts were incubated with increasing amounts of GB, and cleavage was assessed by immunoblotting. B23 was refractory to cleavage in normal and nontumor liver lysates, but was efficiently cleaved in liver tumor lysates (Fig. 2C) .
M
Ϫ1 ⅐s Ϫ1 ; P ϭ 0.04) (Fig. 2D) . Processing of the caspase 3 precursor by GB occurred with comparable efficiency in the tumor and nontumor liver extracts (Fig. 2C) , indicating that resistance of B23 to GB proteolysis in the nontumorous liver extracts was not caused by a general inactivity of the protease.
Because the polyclonal antibody against whole B23 recognizes B23 fragments poorly, we used a peptide-specific antibody (R3956) that specifically recognizes the eight amino acids upstream of the GB cleavage site at D 161 to address whether distinct B23 fragments were being produced by GB cleavage of tumor extracts. Antibody R3956 immunoblots only the N-terminal GB cleavage fragment of B23 (resulting from cleavage at LAAD 161 ) and does not detect intact B23. When the same samples were immunoblotted with this antibody, a specific 22-kDa fragment of B23 was demonstrated in the liver tumor extracts, with even very low concentrations (5.4 nM) of GB (Fig. 2C) . At the highest concentration of GB used (108 nM), the amount of B23 fragment in the tumor extract exceeded that in the normal and nontumorous liver extracts by 15-and 12-fold, respectively. This fragment was not detected in any of the extracts when GB was omitted. Cleavage of NOR-90 by GB in the different liver extracts could not be assessed because the intact protein was degraded after incubating lysates at 37°C in the absence of GB (data not shown).
B23 Localization Is Altered in Neoplastic Hepatocytes in HCC.
To investigate the mechanism determining the selective susceptibility of B23 to GB-mediated proteolysis in liver tumor extracts, B23 localization in tumor and nontumor hepatocytes was examined by staining HCC liver paraffin sections with R3434 antibody. A striking difference was observed: nontumor hepatocytes showed a predominantly cytoplasmic staining pattern for B23, whereas B23 staining in tumor hepatocytes was restricted to the nucleus͞nucleolus (Fig. 3) . Specificity of the diffuse cytoplasmic staining in nontumor hepatocytes was confirmed by competition of R3434 with recombinant B23 (data not shown).
Because GB activity was similar in tumor and nontumor lysates, yet tumor B23 was significantly more sensitive to cleavage by GB, we reasoned that the GB cleavage site in tumor B23 might be more accessible to the protease. Considering that GB specificity resides substantially in recognition of amino acids N-terminal to the scissile bond (24, 25) and that the peptidespecific antibody R3956 recognizes the eight amino acids upstream of this bond at D 161 , we determined the ability of R3956 to recognize its epitope in sections serial to those examined with R3434 above. Interestingly, R3956 showed very prominent nucleolar staining in the majority of tumor hepatocytes (Fig. 3) , despite the lack of GB fragments detected by immunoblotting B23 in extracts of tumor liver (Fig. 2C) . This striking nucleolar staining pattern was observed in neoplastic hepatocytes of all liver tumors examined to date, derived from patients with typical HCC (n ϭ 3) and patients with the fibrolammelar variant of HCC (n ϭ 2), but not in liver adenoma (n ϭ 1) (data not shown). Nucleolar staining was abolished by competition with the cognate peptide, confirming specificity (data not shown). Nontumor hepatocytes did not stain with R3956, although very faint nucleolar staining could be detected in some nontumor hepatocytes in cirrhotic regions (Fig. 3) . Hence, while the R3956 antibody is highly specific for GB-cleaved B23 under denaturing conditions (immunoblotting), it recognizes its epitope in immunohistochemistry of tumor hepatocytes even in the absence of B23 cleavage. R3956 is therefore a probe that demonstrates a unique nucleolar form of B23 in which the GB cleavage site at D 161 is both accessible for antibody binding and cleavage by GB. The highly selective staining of tumor hepatocyte nucleoli with this antibody may be of potential clinical utility in the early detection of liver neoplasia in at-risk groups.
Analysis of Molecular Differences Between the Forms of B23 Expressed in Tumor Versus
Normal Liver. The molecular nature of the difference between B23 in non-neoplastic and neoplastic liver was next addressed. Because of the slightly increased mobility of liver tumor B23 on SDS͞PAGE, and our inability to detect common posttranslational modifications of B23 in tumors, we focused on alterations that could potentially result in a slight decrease in molecular weight. Because alternative translation initiation of B23 appears to occur in vitro during IVTT, generating two forms of B23 that migrate within 1 kDa of each other by SDS͞PAGE (Figs. 1 and 4A) , we investigated whether an N-terminal truncation of B23 produces the unusual sensitivity to GB observed in tumor lysates. B23 contains four methionine residues within the first nine amino acids, one of which (M 7 ) occurs in the context of a consensus kozak sequence. A construct was therefore made lacking the first six codons of B23, with translation beginning at M 7 (M7-B23). M7-B23 produced by IVTT migrated identically on SDS͞PAGE to the B23 species observed in HCC lysates.
M7-B23 showed a striking tendency to form SDS-stable oligomers, which was not a feature of the full-length protein (Fig.  4A) . This difference was evident when samples were boiled in 2% SDS before electrophoresis and was prominent when gel samples were prepared in buffer containing 0.1% SDS, without boiling. Under these conditions, M7-B23 migrated exclusively as an SDS-stable oligomer. Of note, whereas WT IVTT B23 migrated as a doublet on SDS͞PAGE (after boiling in 2% SDS), the lower molecular weight product in this doublet (which comigrates with M7-B23), but not the full-length product, disappeared upon electrophoresis in low (0.1%) SDS-containing sample buffer, with concomitant formation of an SDS-stable oligomer (Fig. 4A) .
To determine whether M7-B23 exhibits enhanced susceptibility to cleavage by GB as was observed for the more rapidly migrating B23 isoform in HCC tumors, in vitro-translated WT and M7-B23 were incubated with GB and electrophoresed by using low SDS conditions. This method of electrophoresis enables the simultaneous comparison of cleaved SDS-stable and SDS-sensitive forms of B23. Interestingly, the SDS-stable oligomeric form of B23 was significantly more sensitive to proteolysis Fig. 3 . Shift in localization of B23 in tumor hepatocytes and recognition by a conformation-specific antibody. Serial liver paraffin sections were stained by immunohistochemistry after antigen retrieval with the R3434 polyclonal anti-B23 antibody (A-C) or the R3956 conformation-specific anti-B23 antibody (D-F). Antibody R3434 stained nontumor hepatocytes with a diffuse cytoplasmic pattern, whereas tumor hepatocytes exhibited nuclear and nucleolar staining. When antibody R3956 was used, normal liver hepatocytes were not stained, nontumor hepatocytes in cirrhotic liver exhibited faint nucleolar staining, and tumor hepatocytes showed dark nucleolar staining. These results are representative of two or more different patients in each category. All images are ϫ100. by GB compared with the SDS-sensitive B23 monomer (6-to 15-fold higher k cat ͞K m in three separate experiments; Fig. 4B ). Of note, cleavage of M7-B23 by GB generated exclusively the 20-and 22-kDa fragments, consistent with cleavage after D 161 (data not shown). Thus, the absence of the first six amino acids of B23 alters the conformation of B23 (SDS-stable oligomer formation), resulting in an enhanced susceptibility to cleavage by GB, and influencing choice of cleavage site.
Because we had previously defined the GB cleavage sites in B23 by using full-length B23 (a mixture of full-length and truncated products) and electrophoresis conditions that do not adequately separate the different B23 isoforms, we repeated the analysis of the cleavage site mutants on the low SDS gel system to resolve the predominant cleavage sites used in the conformationally distinct B23 isoforms. The SDS-stable oligomeric form of WT B23 was efficiently cleaved by GB. Although the D 122 A mutation had no effect on the cleavage of B23 by GB, the D 161 A mutation abolished cleavage of the SDS-stable B23 oligomer (Fig. 4C) . Thus, the D 122 A and D 161 A mutations had distinct effects on GB-mediated proteolysis of the B23 SDSstable oligomer, with D 161 serving as the exclusive GB cleavage site in this isoform.
Finally, to address whether B23 from neoplastic liver exists in an SDS-stable oligomer (as is the case for M7-B23), liver extracts were electrophoresed by SDS͞PAGE in sample buffer containing 0.1% SDS without boiling. The SDS-stable oligomeric form of B23 was immunoblotted in liver tumor, but not in normal or cirrhotic liver (Fig. 4D) . However, the B23 oligomer could be immunoblotted in all three liver extracts after nondenaturing PAGE (0% SDS; data not shown). Thus, whereas B23 normally exists as an oligomer, only B23 in neoplastic liver is present in an SDS-stable conformation, demonstrating that liver tumor B23 is conformationally distinct.
Discussion
In these studies, we have used HCC, the HCC autoantigen B23, and cleavability by GB to define the unique features of diseasespecific autoantigens and their intersection with this protease in the relevant disease microenvironment. Our choice of B23 and HCC was based on several considerations: (i) B23 is an autoantigen targeted in systemic autoimmunity and cancer; (ii) B23 autoantibodies are found in patients with HCC, and in some cases antinucleolar antibody detection coincides with tumor discovery (17); (iii) tumor and relevant control tissues are available for biochemical and immunhistochemical analysis; (iv) the transformed cells are prominently represented in the tumor tissue; and (v) B23 is efficiently cleaved by GB in vitro, but is poorly cleaved during cytotoxic lymphocyte granule-induced death of most cells (unpublished data). Strikingly, B23 was resistant to cleavage by GB in extracts of normal or cirrhotic liver, but was highly susceptible to cleavage in HCC. This resistance to cleavage was B23-specific, as GB activity against another substrate (caspase-3 precursor) was similar in HCC and control livers. Further attempts were made to address the specificity of this phenomenon by examining the GB cleavage susceptibility of six other autoantigens targeted by patient autoantibodies in cancer or systemic autoimmune disease (NOR-90, Mi-2, PARP, c-myc, DNA-PK cs , and topoisomerase II␤). However, immunoblotting of these antigens in the liver extracts revealed either very low levels of expression or expression exclusively in the tumor (NOR-90), precluding such analysis. Of the autoantigens examined, only the HCC autoantigens B23 and NOR-90 were highly expressed in the liver tumor; such high levels of autoantigen expression might be required for their targeting by an autoimmune response.
The basis of the enhanced sensitivity of B23 to cleavage in tumors is the expression of a unique B23 conformation in tumor hepatocytes. Thus, tumor B23 migrates slightly more rapidly on SDS͞PAGE than its nontumor counterpart, is found as an SDS-stable oligomer, has a distinct subcellular distribution, and reacts with the conformation-specific R3956 antibody directed against the GB cleavage site upstream of D 161 , whereas nontumor B23 does not. Notably, the staining of tumor hepatocyte nucleoli with R3956 correlated with the nuclear͞nucleolar localization of B23 (visualized with antibody R3434 recognizing full-length B23), whereas an absence of R3956 staining in nontumor hepatocytes correlated with a predominantly cytoplasmic distribution of B23 in those cells. Because the R3956 antibody stained the vast majority of tumor hepatocytes, it is unlikely that an increase in mitotic index is sufficient to account for the unique conformation of B23 in neoplastic liver. Together, these findings suggest that during liver tumorigenesis, an alteration in B23 conformation (with exposure of the LAAD 161 GB recognition sequence), accompanied by a shift in B23 localization to the nucleolus, results in a significantly increased susceptibility of B23 to cleavage by GB.
Interestingly, the GB cleavage site at D 161 is markedly affected by the conformational changes that occur in tumor B23. This is reflected by both the increased susceptibility of tumor B23 to cleavage by GB and the exposure of this cleavage site to the conformation-specific antibody (R3956) exclusively in neoplastic liver. These data demonstrate that the GB cleavage loop in B23 is in a conformationally highly mobile region of the molecule. Because conformation generally determines function, and because the loop-exposed conformation is expressed exclusively in tumors, it will be important to define any functional differences associated with the distinct conformational states of B23.
The biochemical basis of the differences between tumor and nontumor B23 most likely represents slight truncation at the N terminus of B23 in the liver tumor. Additional studies using MS will be needed to directly confirm this alteration in HCC, but are complicated by the insolubility of the tumor form (data not shown). Of note, in vitro-generated N-terminally truncated B23 beginning at M 7 behaves identically to tumor B23. The striking and unexpected conformational effects of removing six amino acids from the N terminus imply that B23 conformational state is regulated by this short region, potentially via its interaction with additional regions on B23. It is possible that B23 conformation is also regulated by posttranslational modifications at the N terminus; defining these may provide important insights into B23 function during different physiologic states.
The mechanisms responsible for generating the uniquely truncated form of B23 in tumor liver are not yet known, but possibilities include alternate initiation of translation of tumor B23 at M 7 , alternative splicing of B23 mRNA, or novel proteolysis limited to the tumor environment. Interestingly, translation of other tumor antigens such as c-myc [targeted in colon cancer (26) ] has been demonstrated to transiently occur at a downstream initiation site in actively dividing cells, as well as constitutively in some tumor cell lines with altered c-myc genes (27) . It will be of interest to define whether expression of unique conformations of antigens in tumors is of general relevance in defining molecules that are selected as tumor antigens.
The unique conformation and the biochemical features of B23 observed exclusively in HCC hepatocytes present several novel mechanistic possibilities that might be relevant to the selection of B23 as a target of autoantibodies in patients with HCC: (i) expression levels of B23 in tumor are increased; (ii) the unique B23 conformation is highly enriched at a single subcellular site (nucleolus); (iii) the N-terminally truncated form of B23 assumes an SDS-stable oligomeric structure; (iv) the novel B23 isoform exposes a cryptic protease cleavage site; and (v) potentially increased Kupffer cell expression of GB during chronic hepatitis C (28) . The existence of this novel isoform, which may not have been presented during development of immunological tolerance, as a stable oligomer at high local concentrations likely contrib-utes to its ability to effectively initiate a primary immune response (29, 30) . Furthermore, recent studies have demonstrated that the presence or absence of single protease cleavage sites can alter the final processing of that antigen and determine which peptides are loaded onto MHC class II molecules for presentation to T cells (31, 32) . It is therefore of great interest that tumor B23 exposes an otherwise cryptic protease cleavage site. We propose that the unique conformation and protease cleavability of tumor B23 in vivo that have been defined in this study provides an opportunity to directly address the processing of, and immune responses to, the relevant immunogenic form of an autoantigen. Studies to demonstrate preferential HCC autoantibody reactivity with the truncated form of B23 and its cleavage products will provide important direct support for the proposed mechanism. Because B23 autoantibodies have also been observed in breast cancer, it is possible that similar B23 changes will be observed in other tumors.
We have previously noted that susceptibility to cleavage by GB is a general feature of many autoantigens targeted across the spectrum of human autoimmune diseases (4) . Despite the strength and specificity of this association, the relevance of susceptibility to cleavage by GB remains unclear. The finding here that the HCC autoantigen, B23, is selectively susceptible to cleavage by GB in liver tumor extracts provides the platform and tools to define the nature of this striking association. We propose that the targeting of many ubiquitously expressed autoantigens by the immune response in specific disorders is a consequence of microenvironment-specific alterations in the disease-relevant autoantigens that serve to unveil nontolerized structure. In addition to potential increases in the expression levels of autoantigens, differences such as posttranslational modifications (33) , alternative initiation of translation (34) , protein͞protein interactions (35, 36) , and͞or alternative splicing may affect autoantigens during the immunizing event, and via novel conformational changes in the vicinity of the GB cleavage site, may serve to facilitate exposure of this cleavage site and͞or cleavage by GB. Further understanding of the mechanism(s) responsible for determining such changes in conformation may have practical implications in both the therapeutic modulation of this response in systemic autoimmune disease and enhancement of this response in tumor immunotherapy.
